Matches in SemOpenAlex for { <https://semopenalex.org/work/W2565331386> ?p ?o ?g. }
Showing items 1 to 87 of
87
with 100 items per page.
- W2565331386 abstract "GSK3 alpha has been shown to be a new target in the treatment of acute myeloid leukemia (AML); however current GSK3 inhibitors are unselective and target both GSK3 alpha and GSK3 beta. Interestingly, a known pan-GSK3 inhibitor LiCl has been previously investigated for the treatment of AML yet has met limited clinical success. This could be partly due to the fact that pan-GSK3 inhibition results in beta-catenin stabilization, which has been shown to mediate hematopoietic self-renewal and leukemogenesis. As beta-catenin stabilization requires inhibition of both kinases and most GSK3 inhibitors target GSK3 alpha and GSK3 beta with equal potency, these compounds may possess some significant limitations. We have previously shown GSK3 alpha to be a prominent target of the intended MET inhibitor tivantinib (ARQ197) and that tivantinib shows some specificity for GSK3 alpha over GSK3 beta. We thus hypothesized that tivantinib would be an effective therapy for the treatment of AML. Consistently, tivantinib potently inhibited cellular viability across several AML cell lines. Using an unbiased, mass-spectrometry based chemical proteomics approach; we confirmed GSK3 alpha (and to a slightly lesser extent GSK3 beta) to be targeted by tivantinib in AML. Tivantinib strongly induced apoptosis as compared to the pan-GSK3 inhibitor LiCl in these cells while LiCl showed larger effects on cell differentiation. Interestingly tivantinib caused less stabilization of beta-catenin as compared to LiCl. Subsequent drug combination studies identified the Bcl-2 inhibitor ABT-199 to synergize with tivantinib and to amplify apoptosis as seen by PARP1 cleavage. Furthermore, the combination of tivantinib with ABT-199 completely abrogated beta-catenin stabilization. Tivantinib was able to significantly inhibit colony formation of primary AML patient bone marrow mononuclear cells (BMNCs) and ABT-199 combination showed significant benefit over tivantinib or ABT-199 alone. In summary, tivantinib has potent anticancer activity in AML based on targeting GSK3 alpha; and tivantinib single agent or combination with ABT-199 may represent a novel and exciting opportunity for the treatment of AML. Citation Format: Brent M. Kuenzi, Lily L. Remsing Rix, Sateesh S. Kunigal, Fumi Kinose, Claire E. Knezevic, Gabriela Wright, Jodi L. Kroeger, Jeffrey E. Lancet, Eric Padron, Uwe Rix. Off-target based drug repurposing opportunities for tivantinib in acute myeloid leukemia. [abstract]. In: Proceedings of the 106th Annual Meeting of the American Association for Cancer Research; 2015 Apr 18-22; Philadelphia, PA. Philadelphia (PA): AACR; Cancer Res 2015;75(15 Suppl):Abstract nr 675. doi:10.1158/1538-7445.AM2015-675" @default.
- W2565331386 created "2017-01-06" @default.
- W2565331386 creator A5006968359 @default.
- W2565331386 creator A5012452779 @default.
- W2565331386 creator A5014273171 @default.
- W2565331386 creator A5014929394 @default.
- W2565331386 creator A5024601043 @default.
- W2565331386 creator A5036882280 @default.
- W2565331386 creator A5041443589 @default.
- W2565331386 creator A5041754278 @default.
- W2565331386 creator A5042983062 @default.
- W2565331386 creator A5050779886 @default.
- W2565331386 date "2015-08-01" @default.
- W2565331386 modified "2023-09-26" @default.
- W2565331386 title "Abstract 675: Off-target based drug repurposing opportunities for tivantinib in acute myeloid leukemia" @default.
- W2565331386 doi "https://doi.org/10.1158/1538-7445.am2015-675" @default.
- W2565331386 hasPublicationYear "2015" @default.
- W2565331386 type Work @default.
- W2565331386 sameAs 2565331386 @default.
- W2565331386 citedByCount "1" @default.
- W2565331386 countsByYear W25653313862020 @default.
- W2565331386 crossrefType "proceedings-article" @default.
- W2565331386 hasAuthorship W2565331386A5006968359 @default.
- W2565331386 hasAuthorship W2565331386A5012452779 @default.
- W2565331386 hasAuthorship W2565331386A5014273171 @default.
- W2565331386 hasAuthorship W2565331386A5014929394 @default.
- W2565331386 hasAuthorship W2565331386A5024601043 @default.
- W2565331386 hasAuthorship W2565331386A5036882280 @default.
- W2565331386 hasAuthorship W2565331386A5041443589 @default.
- W2565331386 hasAuthorship W2565331386A5041754278 @default.
- W2565331386 hasAuthorship W2565331386A5042983062 @default.
- W2565331386 hasAuthorship W2565331386A5050779886 @default.
- W2565331386 hasConcept C103637391 @default.
- W2565331386 hasConcept C181199279 @default.
- W2565331386 hasConcept C182979987 @default.
- W2565331386 hasConcept C185592680 @default.
- W2565331386 hasConcept C203014093 @default.
- W2565331386 hasConcept C2778461978 @default.
- W2565331386 hasConcept C2778480876 @default.
- W2565331386 hasConcept C2778729363 @default.
- W2565331386 hasConcept C2780035454 @default.
- W2565331386 hasConcept C502942594 @default.
- W2565331386 hasConcept C55493867 @default.
- W2565331386 hasConcept C71924100 @default.
- W2565331386 hasConcept C82381507 @default.
- W2565331386 hasConcept C98274493 @default.
- W2565331386 hasConceptScore W2565331386C103637391 @default.
- W2565331386 hasConceptScore W2565331386C181199279 @default.
- W2565331386 hasConceptScore W2565331386C182979987 @default.
- W2565331386 hasConceptScore W2565331386C185592680 @default.
- W2565331386 hasConceptScore W2565331386C203014093 @default.
- W2565331386 hasConceptScore W2565331386C2778461978 @default.
- W2565331386 hasConceptScore W2565331386C2778480876 @default.
- W2565331386 hasConceptScore W2565331386C2778729363 @default.
- W2565331386 hasConceptScore W2565331386C2780035454 @default.
- W2565331386 hasConceptScore W2565331386C502942594 @default.
- W2565331386 hasConceptScore W2565331386C55493867 @default.
- W2565331386 hasConceptScore W2565331386C71924100 @default.
- W2565331386 hasConceptScore W2565331386C82381507 @default.
- W2565331386 hasConceptScore W2565331386C98274493 @default.
- W2565331386 hasLocation W25653313861 @default.
- W2565331386 hasOpenAccess W2565331386 @default.
- W2565331386 hasPrimaryLocation W25653313861 @default.
- W2565331386 hasRelatedWork W1829282773 @default.
- W2565331386 hasRelatedWork W1986515786 @default.
- W2565331386 hasRelatedWork W1994043858 @default.
- W2565331386 hasRelatedWork W2011093628 @default.
- W2565331386 hasRelatedWork W2019142623 @default.
- W2565331386 hasRelatedWork W2029663510 @default.
- W2565331386 hasRelatedWork W2119335520 @default.
- W2565331386 hasRelatedWork W2219842967 @default.
- W2565331386 hasRelatedWork W2316394408 @default.
- W2565331386 hasRelatedWork W2318778072 @default.
- W2565331386 hasRelatedWork W2332666050 @default.
- W2565331386 hasRelatedWork W2533760929 @default.
- W2565331386 hasRelatedWork W2561229991 @default.
- W2565331386 hasRelatedWork W2601746694 @default.
- W2565331386 hasRelatedWork W2606117552 @default.
- W2565331386 hasRelatedWork W2920795601 @default.
- W2565331386 hasRelatedWork W2955062045 @default.
- W2565331386 hasRelatedWork W2967489068 @default.
- W2565331386 hasRelatedWork W3041783451 @default.
- W2565331386 hasRelatedWork W2473800853 @default.
- W2565331386 isParatext "false" @default.
- W2565331386 isRetracted "false" @default.
- W2565331386 magId "2565331386" @default.
- W2565331386 workType "article" @default.